ArticleACS synthetic biology2020
Expanding the CRISPR Toolbox in Culicine Mosquitoes:
Article in ACS synthetic biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Engineered promoter system enables high-efficiency transgenic CRISPR editing in Malaria transmitting mosquitoZoological research · 2026Article
- Arthropod promoters for genetic control of disease vectors.Trends in parasitology · 2024Review
- A multiplexed, confinable CRISPR/Cas9 gene drive can propagate in caged Aedes aegypti populations.Nature communications · 2024Article
- AePUb promoter length modulates gene expression in Aedes aegypti.Scientific reports · 2023Article
- Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine.The EPMA journal · 2023Review
- Validation of CRISPR activation system inFrontiers in bioengineering and biotechnology · 2023Article
- Use of Insect Promoters in Genetic Engineering to Control Mosquito-Borne Diseases.Biomolecules · 2022Review
- Optimized In Vitro CRISPR/Cas9 Gene Editing Tool in the West Nile Virus Mosquito Vector,Insects · 2022Article
- Intron-derived small RNAs for silencing viral RNAs in mosquito cells.PLoS neglected tropical diseases · 2022Article
- The Challenges in Developing Efficient and Robust Synthetic Homing Endonuclease Gene Drives.Frontiers in bioengineering and biotechnology · 2022Review
- Bioinformatic and cell-based tools for pooled CRISPR knockout screening in mosquitos.Nature communications · 2021Article
- Novel synthetic 3'-untranslated regions for controlling transgene expression in transgenicRNA biology · 2021Article
- CRISPR/Cas-9 mediated knock-in by homology dependent repair in the West Nile Virus vector Culex quinquefasciatus Say.Scientific reports · 2021Article
- Optimized CRISPR tools and site-directed transgenesis towards gene drive development in Culex quinquefasciatus mosquitoes.Nature communications · 2021Article
- A selectable, plasmid-based system to generate CRISPR/Cas9 gene edited and knock-in mosquito cell lines.Scientific reports · 2021Article
- Cas13b-dependent and Cas13b-independent RNA knockdown of viral sequences in mosquito cells following guide RNA expression.Communications biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
CRISPR-Cas9-based "gene drive" technologies have been proposed as a novel and effective means of controlling human diseases vectored by mosquitoes. However, more complex designs than those demonstrated to date-and an expanded molecular toolbox with which to build them-will be required to overcome the issues of resistance formation/evolution and drive spatial/temporal limitation. Foreseeing this need, we assessed the sgRNA transcriptional activities of 33 phylogenetically diverse insect Polymerase III promoters using three disease-relevant Culicine mosquito cell lines (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.